Myelodysplastic Syndromes (MDS)

Imetelstat Improves Rate of Durable Transfusion Independence in Patients With Lower-Risk MDS

Original Publication Date

January 1, 2021

Article Source

External Web Content

Treatment with imetelstat, a competitive inhibitor of telomerase enzymatic activity, was associated with a clinically meaningful rate of transfusion independence in heavily transfused patients with lower-risk myelodysplastic syndromes (MDS), according to study results published…

Overcoming Clinical Challenges Associated With TP53-Mutant MDS, AML

Original Publication Date

December 15, 2020

Article Source

External Web Content

TP53-mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival. Across TP53-altered MDS and AML…

Martha L. Arellano, MD

Institution

Emory University

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

About

Martha L. Arellano, MD, is an Associate Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine where she serves as Associate Director of the Division of Hematology. Board certified in hematology, medical oncology and internal medicine, Dr. Arellano specializes in the treatment of leukemia and myelodysplastic syndromes. She started practicing with Emory Healthcare in 2006. Dr. Arellano is a clinical member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. She currently leads the

Read more about Martha L. Arellano, MD

Guadecitabine Maintenance Therapy Shows Promise in High Risk MDS/AML Patients

Original Publication Date

December 8, 2020

Article Source

External Web Content

Guadecitabine (SGI-110), when given as maintenance therapy following allogeneic stem cell transplantation (allo-SCT), showed promising relapse-free survival rates (RFS) with manageable safety in high-risk patients with myelodysplastic syndromes/acute myeloid leukemia (MDS/AML)…

GTB-3550 TriKE Stimulates Natural Killer Cell Function in MDS and AML

Original Publication Date

December 5, 2020

Article Source

External Web Content

December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia. GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk…

Existing agents, novel agents, or transplantation for high-risk MDS

Read more about Existing agents, novel agents, or transplantation for high-risk MDS

The decision algorithm for treatment of advanced myelodysplastic syndrome (MDS) (intermediate- to very high-risk by the revised International Prognostic Scoring System

Therapy for lower-risk MDS

Read more about Therapy for lower-risk MDS

Lower-risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders whe

Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents

Read more about Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

Read more about A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

This study investigated the efficacy and safety of azacitidine azacitidine: It works by reducing the amount of methylation in the body.

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Read more about A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative option for myelodysplastic syndromes myelodysplast

Subscribe to Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

Imetelstat Improves Rate of Durable Transfusion Independence in Patients With Lower-Risk MDS

Overcoming Clinical Challenges Associated With TP53-Mutant MDS, AML

Martha L. Arellano, MD

Guadecitabine Maintenance Therapy Shows Promise in High Risk MDS/AML Patients

GTB-3550 TriKE Stimulates Natural Killer Cell Function in MDS and AML

Existing agents, novel agents, or transplantation for high-risk MDS

Therapy for lower-risk MDS

Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Website Feedback

Patient Helpline